Navigation Links
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Date:9/2/2008

id and significant pain reduction in endometriosis symptoms," said Chris O'Brien, MD, Chief Medical Officer at Neurocrine. "Additionally, this study confirms our decision to move forward with once daily dosing."

Secondary endpoints for the PETAL study were evaluated to assess the improvement of endometriosis symptoms following treatment with elagolix. Improvement in endometriosis symptoms was documented using several different scales for endometriosis pain. The following were assessed before, during and after the six months of treatment:

-- Total Composite Pelvic Sign and Symptoms Score (CPSSS), a validated

0-15 scale that assesses five components of endometriosis pain

severity, each on a 0-3 scale.

-- Dysmenorrhea (pelvic pain during menstruation), a component of the

CPSSS; 0-3 scale (0=absence of pain, 1=mild pain, 2=moderate pain,

3=severe pain)

-- 98% of patients at baseline had moderate or severe dysmenorrhea.

-- Non-menstrual pelvic pain (pelvic pain outside of menstruation), a

component of the CPSSS; 0-3 scale (0=absence of pain, 1=mild pain,

2=moderate pain, 3=severe pain)

-- 97% of patients at baseline had moderate or severe non-menstrual

pelvic pain.

-- Responder Rate, percentage of patients who had a one point or greater

decrease in pain score.

-- Visual Analog Scale (VAS) to assess pelvic pain levels using daily

electronic diary.

Elagolix provided a clinically meaningful and statistically significant reduction in endometriosis pain from baseline as shown below. The magnitude of improvement is comparable to that demonstrated with the currently approved agents, leuprolide and DMPA.

Screening Elagolix

Baseline 150mg qd 75mg bid DMPA

CPSSS 9.1

Week 4 mean -3.9
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... SAN DIEGO , July 11, 2014 ... Therapies Corp. ("Biotie") to end the option held by ... to commence further development of NRL-1 (intranasal diazepam) for ... seizures. Over the past year, Biotie has ... Neurelis in preparation for the pivotal clinical work required ...
(Date:7/10/2014)... 10, 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... and analog IC solutions, today announced that it will ... 2014, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern ... fiscal 2014 third quarter ended June 30, 2014. ... 1-888-556-4997 before 6:50 a.m. Pacific time on July 24, ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical ... today announced it has entered into an agreement with ... operates as EMD Serono in the United ... to collaborate with Merck KGaA,s biopharmaceutical division on the ... an undisclosed target using Ventana,s proprietary diagnostic assays. In ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
(Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives ... Application & Geography – Trends & Forecast to 2018," ... forecasting of market volume and value. The report also ... The market of phthalic anhydride is projected to grow ... million by 2018, with a CAGR of 5.24% from ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... 2014 The fastest-growing mobile technology is ... measurement of LTE networks continues to grow due to ... devices have increased mobile data traffic, which is a ... market. Communications Test and Measurement equipment comply with industry ... Communications Test and Measurement Market is estimated to grown ...
(Date:7/12/2014)... News) -- If you make exercise fun, you,ll eat less ... 56 adults were led on a 1.4-mile walk and were ... scenic walk. The participants were given lunch after the walk, ... ate 35 percent more chocolate pudding for dessert than those ... another experiment, 46 adults were given mid-afternoon snacks after their ...
(Date:7/12/2014)... ON Canada (PRWEB) July 12, 2014 Sean Francis, ... for throwing out special challenges to his clients. He’s also known ... Club. He recently found a way to combine the two and ... has raised $2,000 for the Boys and Girls Club. , The ... Program, which started on June 23rd. Francis sent out emails and ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3
... ... ... ... ...
... ... , ... , , , ... NEW YORK , March 4 ...
... ... ... ... ...
... third leading cause of cancer death among men and ... CRC screening receive it. The American Gastroenterological Association (AGA) ... of screening and to encourage everyone age 50 and ... that those without insurance have limited access to screening, ...
... Calculus Bovis compound preparation (ICCBco) in the treatment ... schistosomiasis as the experimental animal model, a research ... trial to observe pathological changes and pathological effect ... the lung tissue of portal hypertensive rabbits with ...
... at risk, but elderly women are too, study finds , ... common cause of shoulder dislocation, and young males have the ... study shows. , Researchers studied 8,940 shoulder dislocations treated at ... to 2006 and found that the overall incidence rate was ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Cowen Group Announces Promotions in Health Care Investment Banking 2Health News:Cowen Group Announces Promotions in Health Care Investment Banking 3Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 2Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 3Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 4Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 5Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 6Health News:Physicians come together on National Colorectal Cancer Awareness and Screening Day 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Shoulder Dislocations a Sports Hazard 2
... breakthrough in specimen radiography. The XPERT represents a ... shades of gray in every digital x-ray image, ... in density that heretofore were lost to the ... 2 x 2 to 8 x 8 in ...
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
... The 6303 is an affordable ... provide full height, seat, and back ... 6303 accepts the full line of ... the perfect table for your needs; ...
... Sonesta 6202 is the ultimate ... our most popular accessories, the ... a myriad of exam and ... quiet) motors allow fast & ...
Medicine Products: